title: The efficacy and safety of pravastatin, compared to and in combination with bile acid binding resins, in familial hypercholesterolaemia.
abstract: Forty patients with familial hypercholesterolaemia (FH) were treated with 40 mg pravastatin once daily. Pravastatin decreased serum total and low density lipoprotein cholesterol (LDL) after 8 weeks of treatment by 28% and 33%, respectively, while high density lipoprotein cholesterol increased by 8% and triglycerides decreased by 14%. In 30 patients LDL cholesterol had not decreased below 5.0 mmol l-1 after 8 weeks of treatment, and in these patients resins were added to pravastatin, resulting in an additional decrease in total and LDL cholesterol of 8% and 12%, respectively. A control group of 22 FH patients was treated with placebo for 10 weeks, after which time resins were added, and they induced a decrease in total and LDL-cholesterol of 17% and 22%, respectively. Our results over a 24-week treatment period indicate that 40 mg pravastatin is more effective than 3 packets of resins in lowering LDL cholesterol, whereas the combination is most effective of all and can be used safely.
authors.affiliation: University Hospital Dijkzigt, Rotterdam, The Netherlands.
authors.forename: N
authors.initials: N
authors.lastname: Hoogerbrugge
authors.forename: M J
authors.initials: MJ
authors.lastname: Mol
authors.forename: J J
authors.initials: JJ
authors.lastname: Van Dormaal
authors.forename: C
authors.initials: C
authors.lastname: Rustemeijer
authors.forename: E
authors.initials: E
authors.lastname: Muls
authors.forename: A F
authors.initials: AF
authors.lastname: Stalenhoef
authors.forename: J C
authors.initials: JC
authors.lastname: Birkenhäger
mesh_terms: D000924:Anticholesteremic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001647:Bile Acids and Salts / Q000627:therapeutic use*; D002352:Carrier Proteins / Q000627:therapeutic use*; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006538:Heptanoic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D006913:Hydroxysteroid Dehydrogenases; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy*; D008297:Male; D008562:Membrane Glycoproteins; D009281:Naphthalenes / Q000009:adverse effects / Q000627:therapeutic use*; D017035:Pravastatin; D016032:Randomized Controlled Trials as Topic; D014280:Triglycerides / Q000097:blood; D045002:3-alpha-Hydroxysteroid Dehydrogenase (B-Specific)
chemical_list: D000924:Anticholesteremic Agents; D001647:Bile Acids and Salts; D002352:Carrier Proteins; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D006538:Heptanoic Acids; D006913:Hydroxysteroid Dehydrogenases; D008562:Membrane Glycoproteins; D009281:Naphthalenes; D017035:Pravastatin; D014280:Triglycerides; C037643:bile acid binding proteins; C435496:AKR1C2 protein, human; D045002:3-alpha-Hydroxysteroid Dehydrogenase (B-Specific)